Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology

66
26
Favorite

Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology

thestreet2021-06-17

Midatech Pharma (MTP) shares soared Thursday after the U.K.-based biotechnology company announced a "breakthrough" in the development of its specialized technology that can form proteins into long-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（26）

CleavonFx
·2022-01-09
.
Reply
Like
Report
Fold Replies
- CleavonFx:
  .
  2022-02-07
  Reply
  Report
- CleavonFx:
  .
  2022-02-05
  Reply
  Report
- CleavonFx:
  .
  2022-02-04
  Reply
  Report
View more 2 comments
Britmand
·2021-06-20
Nice
Reply
Like
Report
Eddygoh
·2021-06-18
good development for the future
Reply
Like
Report
Jia jia
·2021-06-18
Balancing
Reply
1
Report
kevinlaisq
·2021-06-18
Comment and like pls
Reply
2
Report
Fold Replies
- henghm:
  like and comment
  2021-06-18
  Reply
  Report
paxxie
·2021-06-18
like anc comment
Reply
2
Report
Fold Replies
- kevinlaisq:
  plssreply back
  2021-06-18
  Reply
  Report
Wes1128
·2021-06-18
??
Reply
1
Report
rongjing88
·2021-06-18
Certainly great to see more developement in the medical industry
Reply
1
Report
JosesSim
·2021-06-18
NICE, Like and comment please
Reply
2
Report
doje
·2021-06-18
Wii
Reply
6
Report
Austin1881
·2021-06-18
Good future!
Reply
3
Report
criticalstud
·2021-06-18
Oh no
Reply
3
Report
Fayna
·2021-06-18
Hopefully can see more drug development in combating cancer as well.
Reply
3
Report
Water188
·2021-06-17
Wow
Reply
3
Report
Fold Replies
- Woohaha:
  xool
  2021-06-18
  Reply
  Report
Koey
·2021-06-17
Great
Reply
3
Report
Cat007
·2021-06-17
Can I have a like please? Ty
Reply
4
Report
CleavonFx
·2021-06-17
.
Reply
2
Report
Fold Replies
- CleavonFx:
  .
  2022-01-16
  Reply
  Report
- CleavonFx:
  .
  2022-01-05
  Reply
  Report
- CleavonFx:
  .
  2021-11-23
  Reply
  Report
View more 2 comments
NgYiXian
·2021-06-17
Nice
Reply
2
Report
azotest
·2021-06-17
Comment
Reply
2
Report
Fold Replies
- Cat007:
  Commented
  2021-06-17
  Reply
  Report
ricky1991
·2021-06-17
To the moon
Reply
Like
Report
Fold Replies
- Missypampam:
  [Miser]
  2021-06-17
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1199020816?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-17 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199020816","market":"us","top_or_hot":-1,"title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","media":"thestreet","content":"<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","article_id":"1199020816","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","pubTimestamp":1623940823,"sourceInfo":null,"weMediaInfo":null,"summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Midatech Pharma凭借“突破性”药物递送技术一飞冲天","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTP":0.9},"content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":694067819,"gmtCreate":1641714897785,"gmtModify":1676532552111,"author":{"id":"3577625682381834","authorId":"3577625682381834","authorIdStr":"3577625682381834","name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577625682381834"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/694067819","repostId":1199020816,"repostType":2,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7233894,"gmtCreate":1644246677588,"gmtModify":1663239753934,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694067819,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7230984,"gmtCreate":1644054958654,"gmtModify":1663239742638,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694067819,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7229763,"gmtCreate":1643979304848,"gmtModify":1663239734942,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694067819,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7165816,"gmtCreate":1641714971663,"gmtModify":1663239444356,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694067819,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7176746,"gmtCreate":1642125146365,"gmtModify":1642125146365,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694067819,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."}],"langContent":"CN"},{"id":165219195,"gmtCreate":1624146000417,"gmtModify":1703829277226,"author":{"id":"3559613619677698","authorId":"3559613619677698","authorIdStr":"3559613619677698","name":"Britmand","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3559613619677698"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165219195","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166020118,"gmtCreate":1623985854034,"gmtModify":1703825694974,"author":{"id":"3574567105251603","authorId":"3574567105251603","authorIdStr":"3574567105251603","name":"Eddygoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574567105251603"},"htmlText":"good development for the future","listText":"good development for the future","text":"good development for the future","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166020118","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168621314,"gmtCreate":1623974489238,"gmtModify":1703824995720,"author":{"id":"3566190997597521","authorId":"3566190997597521","authorIdStr":"3566190997597521","name":"Jia jia","avatar":"https://static.tigerbbs.com/a5e41a8432102fa946fee83eeb1384d7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3566190997597521"},"htmlText":"Balancing","listText":"Balancing","text":"Balancing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168621314","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168681105,"gmtCreate":1623973942807,"gmtModify":1703824970306,"author":{"id":"3572874548548490","authorId":"3572874548548490","authorIdStr":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572874548548490"},"htmlText":"Comment and like pls","listText":"Comment and like pls","text":"Comment and like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/168681105","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4851653,"gmtCreate":1623974784212,"gmtModify":1663229215344,"authorId":3578451349447391,"author":{"id":3578451349447391,"authorId":3578451349447391,"name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":168681105,"type":1,"supId":0,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"}],"langContent":"EN"},{"id":168141079,"gmtCreate":1623968404891,"gmtModify":1703824749283,"author":{"id":"3559522411638426","authorId":"3559522411638426","authorIdStr":"3559522411638426","name":"paxxie","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3559522411638426"},"htmlText":"like anc comment&nbsp;","listText":"like anc comment&nbsp;","text":"like anc comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/168141079","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4851230,"gmtCreate":1623973963790,"gmtModify":1663229212728,"authorId":3572874548548490,"author":{"id":3572874548548490,"authorId":3572874548548490,"name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":168141079,"type":1,"supId":0,"prevId":0,"content":"plssreply back","text":"plssreply back","html":"plssreply back"}],"langContent":"EN"},{"id":168103679,"gmtCreate":1623956949191,"gmtModify":1703824643623,"author":{"id":"3581674775775674","authorId":"3581674775775674","authorIdStr":"3581674775775674","name":"Wes1128","avatar":"https://static.tigerbbs.com/05c237da04020bc3bc8f5d1496b4d440","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581674775775674"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168103679","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168376507,"gmtCreate":1623955958909,"gmtModify":1703824634721,"author":{"id":"3574998035612078","authorId":"3574998035612078","authorIdStr":"3574998035612078","name":"rongjing88","avatar":"https://static.tigerbbs.com/ef155649db47180da73ec02dece94b8b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574998035612078"},"htmlText":"Certainly great to see more developement in the medical industry&nbsp;","listText":"Certainly great to see more developement in the medical industry&nbsp;","text":"Certainly great to see more developement in the medical industry","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168376507","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168350506,"gmtCreate":1623952888005,"gmtModify":1703824600681,"author":{"id":"3579481478181513","authorId":"3579481478181513","authorIdStr":"3579481478181513","name":"JosesSim","avatar":"https://static.tigerbbs.com/853019efea44fd1496df9ca6c8c210cc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3579481478181513"},"htmlText":"NICE, Like and comment please","listText":"NICE, Like and comment please","text":"NICE, Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168350506","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168300343,"gmtCreate":1623948527782,"gmtModify":1703824503130,"author":{"id":"3581991231766444","authorId":"3581991231766444","authorIdStr":"3581991231766444","name":"doje","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581991231766444"},"htmlText":"Wii","listText":"Wii","text":"Wii","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168300343","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168946437,"gmtCreate":1623948009929,"gmtModify":1703824483056,"author":{"id":"3573986007929989","authorId":"3573986007929989","authorIdStr":"3573986007929989","name":"Austin1881","avatar":"https://static.tigerbbs.com/45829b3f97aeccca06b4274184f0d6e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573986007929989"},"htmlText":"Good future!","listText":"Good future!","text":"Good future!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168946437","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168981195,"gmtCreate":1623946751517,"gmtModify":1703824424355,"author":{"id":"3578879337895301","authorId":"3578879337895301","authorIdStr":"3578879337895301","name":"criticalstud","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578879337895301"},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168981195","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168989252,"gmtCreate":1623946699976,"gmtModify":1703824421538,"author":{"id":"3576151042223854","authorId":"3576151042223854","authorIdStr":"3576151042223854","name":"Fayna","avatar":"https://community-static.tradeup.com/news/04ea830c5237c9a4406b40ae311461e8","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3576151042223854"},"htmlText":"Hopefully can see more drug development in combating cancer as well.","listText":"Hopefully can see more drug development in combating cancer as well.","text":"Hopefully can see more drug development in combating cancer as well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168989252","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168041045,"gmtCreate":1623945354987,"gmtModify":1703824340561,"author":{"id":"3574214794839908","authorId":"3574214794839908","authorIdStr":"3574214794839908","name":"Water188","avatar":"https://static.tigerbbs.com/e000bc72e6b41fa9a6729312fd1d1cf1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574214794839908"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/168041045","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4844685,"gmtCreate":1623946344851,"gmtModify":1663229181333,"authorId":3574854234943753,"author":{"id":3574854234943753,"authorId":3574854234943753,"name":"Woohaha","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":168041045,"type":1,"supId":0,"prevId":0,"content":"xool","text":"xool","html":"xool"}],"langContent":"EN"},{"id":168025329,"gmtCreate":1623944737961,"gmtModify":1703824320584,"author":{"id":"3555258134444739","authorId":"3555258134444739","authorIdStr":"3555258134444739","name":"Koey","avatar":"https://static.tigerbbs.com/b00aea8cc65a7b91263ae19adeaa9eee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555258134444739"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168025329","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168091769,"gmtCreate":1623942924851,"gmtModify":1703824244022,"author":{"id":"3574851222459099","authorId":"3574851222459099","authorIdStr":"3574851222459099","name":"Cat007","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574851222459099"},"htmlText":"Can I have a like please? Ty","listText":"Can I have a like please? Ty","text":"Can I have a like please? Ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168091769","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161774779,"gmtCreate":1623942311791,"gmtModify":1703824222574,"author":{"id":"3577625682381834","authorId":"3577625682381834","authorIdStr":"3577625682381834","name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577625682381834"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":13,"repostSize":0,"link":"https://ttm.financial/post/161774779","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7182654,"gmtCreate":1642315649005,"gmtModify":1663239518635,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161774779,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":7156142,"gmtCreate":1641363217569,"gmtModify":1663239399242,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161774779,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":6689731,"gmtCreate":1637642196780,"gmtModify":1663237422844,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161774779,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":6597718,"gmtCreate":1637040986566,"gmtModify":1663237026935,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161774779,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":6200252,"gmtCreate":1634232753178,"gmtModify":1663235377343,"authorId":3577625682381834,"author":{"id":3577625682381834,"authorId":3577625682381834,"name":"CleavonFx","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161774779,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."}],"langContent":"EN"},{"id":161776588,"gmtCreate":1623942205644,"gmtModify":1703824218815,"author":{"id":"3572863789093722","authorId":"3572863789093722","authorIdStr":"3572863789093722","name":"NgYiXian","avatar":"https://static.tigerbbs.com/6b91d3a1d33d08224be3f233ec5b315d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572863789093722"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161776588","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161773726,"gmtCreate":1623942098765,"gmtModify":1703824215086,"author":{"id":"3579653595425309","authorId":"3579653595425309","authorIdStr":"3579653595425309","name":"azotest","avatar":"https://static.tigerbbs.com/9bd8f412814fbaeb758280a91014dd5a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3579653595425309"},"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161773726","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4843016,"gmtCreate":1623942887999,"gmtModify":1663229174330,"authorId":3574851222459099,"author":{"id":3574851222459099,"authorId":3574851222459099,"name":"Cat007","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161773726,"type":1,"supId":0,"prevId":0,"content":"Commented","text":"Commented","html":"Commented"}],"langContent":"EN"},{"id":161747567,"gmtCreate":1623941963459,"gmtModify":1703824210706,"author":{"id":"3564454055125110","authorId":"3564454055125110","authorIdStr":"3564454055125110","name":"ricky1991","avatar":"https://static.tigerbbs.com/2097e02b6c69dfa784759e6bd21b97ae","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":8,"crmLevelSwitch":1,"idStr":"3564454055125110"},"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161747567","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","pubTimestamp":1623940823,"share":"https://ttm.financial/m/news/1199020816?lang=&edition=fundamental","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma&nbsp;(<b>MTP</b>) &nbsp;shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p>\n<p>Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p>\n<p>Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p>\n<p>How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p>\n<p>“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p>\n<p>“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p>\n<p>The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p>\n<p>Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-...</p>\n\n<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP)  shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4842736,"gmtCreate":1623942154917,"gmtModify":1635313416894,"authorId":3576253972603112,"author":{"id":3576253972603112,"authorId":3576253972603112,"name":"Missypampam","avatar":"https://static.tigerbbs.com/25229e3836d82fa58ebf76e52af13677","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161747567,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":66,"commentSize":26,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}